Article Text

▼Glatiramer acetate for multiple sclerosis
  • Relevant BNF section: 8.2.4


&#9660Glatiramer* acetate (Copaxone - Teva) was first marketed in the UK last year as a treatment for reducing the "frequency of relapses in ambulatory patients with relapsing-remitting multiple sclerosis characterised by at least one clinical relapse over the preceding two-year period".1 Here, we assess the place of this drug.

Statistics from

  • Relevant BNF section: 8.2.4

View Full Text


    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.